To Bridge or Not to Bridge: Perioperative Anticoagulation Bridging Risks, Guidelines, and Strategies in Hospitalized Patients
Manage episode 523012810 series 3692609
In this episode of Hospital Medicine Unplugged, we hit the brakes on routine bridging—who actually needs LMWH/UFH when you stop warfarin, and who is safer with no bridge at all?
We start by nailing the definition: bridging = temporarily swapping a long-acting oral anticoagulant (usually warfarin) for short-acting heparin (UFH/LMWH) during interruptions for procedures or bleeding. Then we zoom out to the core tension: tiny peri-procedural thromboembolic risk vs a 3–4× jump in major bleeding with bridging.
We walk through thromboembolic risk stratification—AF with CHA₂DS₂-VASc, recent VTE timing, mechanical valves, and severe thrombophilia—and pair it with procedure and patient bleeding risk (neurosurgery vs dental work, HAS-BLED factors, renal/liver disease, prior bleeds).
Then comes the evidence gut-punch:
BRIDGE: in AF on warfarin, no reduction in thromboembolism, but major bleeding triples with LMWH bridging.
Meta-analyses: no thrombotic benefit, big bleeding signal across mixed AF/VTE/mechanical valve cohorts.
PAUSE & DOAC data: rapid onset/offset means DOACs almost never need bridging.
From there we carve out the true bridging exceptions—the “maybe yes” group:
• Mechanical mitral or older-generation mechanical valves
• Very recent (<3 months) VTE or stroke/systemic embolism
• Severe thrombophilia or high-risk cancer-associated VTE
Everywhere else, guidelines increasingly say: “Don’t bridge.” Most AF, remote VTE, bileaflet mechanical AVR without extra risk factors, and all DOAC-treated patients go down a simple interrupt-and-restart pathway instead of heparin drips and syringes.
We close with a practical, ward-ready playbook:
• Step 1: Classify thromboembolic risk (AF/VTE/valve).
• Step 2: Classify procedure + patient bleeding risk.
• Step 3: If DOAC → timed hold based on drug + kidney function, no bridge.
• Step 4: If warfarin and truly very high thrombotic risk → consider LMWH/UFH, but delay/avoid post-op therapeutic dosing when bleeding risk is high.
• Step 5: Use prophylactic-dose LMWH as VTE prophylaxis, not as a stealth “mini-bridge.”
By the end, you’ll have a clean mental algorithm for “bridge vs no bridge” that lines up with ACCP, AHA/ACC, and AF guidelines—less bleeding, same stroke protection, and far fewer unnecessary heparin shots.
126 episodes